China Health Industries Holdings (China Health Industries Holdings) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is China Health Industries Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of China Health Industries Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of China Health Industries Holdings's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, China Health Industries Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Health Industries Holdings's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Health Industries Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where China Health Industries Holdings's Risk Assessment falls into.

China Health Industries Holdings (OTCPK:CHHE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

China Health Industries Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of China Health Industries Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

China Health Industries Holdings (China Health Industries Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Health Industries Holdings Inc (OTCPK:CHHE) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3199-1 Longxiang Road, Songbei District, Heilongjiang Province, Harbin, CHN, 150028

Website

http://www.chinahealthindustries.com

China Health Industries Holdings Inc operates in the health product industry and produces, markets and distributes medicines, health products, health devices and cosmetics. Its products series cover hemp-based food, hemp-based medicines, external used medicines and health food. The company has segmented its operating activities into three reportable segments, Humankind, HLJ Huimeijia, and Others. It generates maximum revenue from the Humankind segment.

Executives

Sun Xin	director, 10 percent owner, officer: CEO, CFO and Treasurer	NO 168 BINBEI STREET, SONBEI DISTRICT, HARBIN, HEI LONG JIANG F4 150000
Hall E Ewing	director, officer: Secretary	2737 W BASELINE RD 22, TEMPE AZ 85283
Jack C Robinson	director	16304 E COUNTRY SHADOW CT, LILBEAT AZ 85297
Teri S Foster	director	402 CANDOVER COURT, KATY TX 77450
Brian Lee Hahn	director, officer: COO	422 LAMONT TERRACE, BUFFALO GROVE IL 60089
Dennis Mckee	10 percent owner	3522 DOHERTY PLACE, KATY TX 77449
Thomas Allen Bontems	10 percent owner, officer: President, CEO, CFO and, other: Secretary	1808 S. 1ST AVENUE, PHONEIX AZ 85003

China Health Industries Holdings (China Health Industries Holdings) Headlines

No Headlines